Novartis
NVS
1,223 hedge funds and large institutions have $15.1B invested in Novartis in 2023 Q3 according to their latest regulatory filings, with 96 funds opening new positions, 375 increasing their positions, 448 reducing their positions, and 60 closing their positions.
60% more first-time investments, than exits
New positions opened: 96 | Existing positions closed: 60
23% more funds holding in top 10
Funds holding in top 10: 13 → 16 (+3)
2% more funds holding
Funds holding: 1,202 → 1,223 (+21)
1% more capital invested
Capital invested by funds: $14.9B → $15.1B (+$156M)
0.01% more ownership
Funds ownership: 6.52% → 6.52% (+0.01%)
6% less call options, than puts
Call options by funds: $253M | Put options by funds: $270M
16% less repeat investments, than reductions
Existing positions increased: 375 | Existing positions reduced: 448
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
+$116M |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
+$69.7M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
+$55.3M |
| 4 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$47.7M |
| 5 |
Renaissance Technologies
New York
|
+$28.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$73.6M |
| 2 |
Primecap Management
Pasadena,
California
|
-$42.2M |
| 3 |
Twin Tree Management
Dallas,
Texas
|
-$41.4M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$31.2M |
| 5 |
Morgan Stanley
New York
|
-$29.2M |
NVS Hedge Fund Activity: Q3 2023 in Review
1,223 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2023, worth a combined $15.1B — up 1% from $14.9B a quarter earlier.
Buyers outnumbered sellers: 96 funds opened new NVS positions and 60 closed out — a net gain of 36 holders — while 375 added to existing stakes and 448 trimmed.
The largest buyer was Grantham, Mayo, Van Otterloo & Co (GMO), adding an estimated $116M. The largest seller was Point72 Asset Management, cutting an estimated $73.6M.
- 1,223 institutional investors held Novartis (NVS) as of Q3 2023, up from 1,202 in Q2 2023.
- Funds reported $15.1B of Novartis stock for Q3 2023, up 1% quarter-over-quarter.
- 96 funds opened new Novartis positions in Q3 2023 and 60 closed out, a net change of +36 holders.
- The largest Novartis buyer in Q3 2023 was Grantham, Mayo, Van Otterloo & Co (GMO), an estimated $116M added.
- The largest Novartis seller in Q3 2023 was Point72 Asset Management, an estimated $73.6M sold.
Based on aggregated 13F filings for Q3 2023.